POEMs
Patient-Oriented Evidence That Matters

Decreased Short-Term Mortality With Steroid Use for Severe Pneumonia and Acute Respiratory Distress Syndrome

Nita Shrikant Kulkarni, MD,
Assistant Professor, Northwestern University, Chicago, Illinois

American Family Physician. 2026;114(5):543A-543B.

Author Disclosure: No relevant financial relationships.

CLINICAL QUESTION

Is there a reduction in mortality in patients with severe pneumonia or acute respiratory distress syndrome (ARDS) who receive adjunct corticosteroids?

BOTTOM LINE

Moderate-certainty evidence showed a reduction in short-term mortality in patients with severe pneumonia or ARDS who received adjunct corticosteroids. (Level of Evidence = 1a−)

SYNOPSIS

The investigators searched multiple databases, including MEDLINE, EMBASE, the Cochrane Library, and Google Scholar for randomized controlled trials that evaluated the effect of adjunct, low-dose, short-course systemic corticosteroids compared with standard care or placebo for the treatment of adult patients hospitalized with non–COVID-19 severe pneumonia or ARDS. Two reviewers independently selected studies, extracted data, and performed a risk-of-bias assessment. Twenty studies met the inclusion criteria: 15 studies enrolled patients with severe pneumonia (n = 2,445) and five enrolled patients with ARDS (n = 1,014). Most studies used hydrocortisone for 7 days. Overall, five of the severe pneumonia studies and one of the ARDS studies were at high risk of bias. Systemic corticosteroids reduced short-term mortality (death within 90 days) with moderate certainty in the severe pneumonia group (relative risk [RR] = 0.73; 95% CI, 0.57–0.93; I2 = 14%) and in the ARDS group (RR = 0.77; 95% CI, 0.61–0.99; I2 = 23%). The mortality benefit appeared to be regardless of dose and type of corticosteroid used. Low-certainty evidence showed that corticosteroids decreased the incidence of secondary shock in patients with severe pneumonia (RR = 0.49; 95% CI, 0.26–0.92; I2 = 55%). Neither group had an increase in hospital-acquired infections.

Study Design: Meta-analysis (randomized controlled trials)

Funding Source: Self-funded or unfunded

Setting: Inpatient (intensive care unit only)

Reference: Schildroth S, Gaston SA, Harmon QE, et al. A prospective study of hair dyes and uterine leiomyomata incidence in the study of environment, lifestyle, and fibroids. Fertil Steril. 2026;125(1):94-105.

Nita Shrikant Kulkarni, MD, Assistant Professor, Northwestern University, Chicago, Illinois

Author Disclosure: No relevant financial relationships.

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com​. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/Home/Loe​.

Primary Care Update, a free podcast focused on POEMs, is available on Apple Podcasts​ and Spotify​.

This series is coordinated by Natasha J. Pyzocha, DO, contributing editor.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.